All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @surgeon.dr.hafiz.gulfam on TikTok · 94s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @surgeon.dr.hafiz.gulfam's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00from the end, to the end,
  2. 0:02to the beginning, to the beginning,
  3. 0:03we have to tell the people that you can't go anywhere
  4. 0:05down but the next question is,
  5. 0:07before the end,
  6. 0:08when you are a person or your mother,
  7. 0:11I'm so glad that you all are already there,
  8. 0:13and you don't have to wait until your relationship is there.
  9. 0:15If you are not there,
  10. 0:17it is very good to see you.
  11. 0:19I'd like to have a better education
  12. 0:22than you would have in your life.
  13. 0:24Yes, let's say you have to have a better education.
  14. 1:28Yeah, 10% of body weight, you know,
  15. 1:30who was coming to this is the other company.
  16. 1:32Thank you.

This surgeon's TikTok skips GLP-1 details entirely

surgeon.dr.hafiz.gulfam

TikTok creator

686.5K viewsWatch on TikTok

Quick answer

The only extractable clinical reference in this video is an apparent claim that GLP-1 therapy produces approximately 10% body weight reduction, which aligns with semaglutide outcomes in controlled trials but understates results seen with tirzepatide and overstates those typically seen with liraglutide. The transcript is otherwise incoherent and does not name any drug, dose, contraindication, or patient population. No actionable or verifiable medical guidance can be derived from the content as presented.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For This surgeon's TikTok skips GLP-1 details entirely, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

This surgeon's TikTok skips GLP-1 details entirely is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "This surgeon's TikTok skips GLP-1 details entirely" from surgeon.dr.hafiz.gulfam. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The only extractable clinical reference in this video is an apparent claim that GLP-1 therapy produces approximately 10% body weight reduction, which aligns with semaglutide outcomes in controlled trials but understates results seen with tirzepatide and overstates those typically seen with liraglutide.

The reason this review is not generic is the source wording and the canonical claim label "glp1 for appointment 03294686026 03096142525 drgulfam bashirhos." In this clip, the useful excerpt is: "from the end, to the end, to the beginning, to the beginning, we have to tell the people that you can't go anywhere down but the next question is, before the end, when you are a person or your mother, I'm so glad that you all are already..." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 (Jastreboff et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The only extractable clinical reference in this video is an apparent claim that GLP-1 therapy produces approximately 10% body weight reduction, which aligns with semaglutide outcomes in controlled trials but understates results seen with tirzepatide and overstates those typically seen with liraglutide.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The only extractable clinical reference in this video is an apparent claim that GLP-1 therapy produces approximately 10% body weight reduction, which aligns with semaglutide outcomes in controlled trials but understates results seen with tirzepatide and overstates those typically seen with liraglutide. The transcript is otherwise incoherent and does not name any drug, dose, contraindication, or patient population. No actionable or verifiable medical guidance can be derived from the content as presented.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced mean 14.9% body weight loss, not 10%, over 68 weeks in adults with obesity.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 22.5% mean weight loss at 15mg, significantly above the figure implied in this video.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced mean 14.9% body weight loss, not 10%, over 68 weeks in adults with obesity.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 22.5% mean weight loss at 15mg, significantly above the figure implied in this video.
  • Liraglutide (Saxenda) typically produces closer to 5-8% body weight loss in real-world settings, well below the 10% figure referenced.
  • GLP-1 agonists carry FDA-labeled contraindications including personal or family history of medullary thyroid carcinoma and MEN2 syndrome; no content in this video acknowledges these.
  • Muscle mass loss alongside fat loss during GLP-1 therapy is an active clinical concern, with Biancalana et al. (2023, Diabetes Care) noting the need for resistance training and protein intake monitoring.
  • A phone number in a TikTok caption does not substitute for a licensed telehealth intake process with documented informed consent and contraindication screening.
  • The transcript of this video is largely incoherent and contains no verifiable, actionable medical claim beyond the single 10% figure, which itself lacks any drug or dose context.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @surgeon.dr.hafiz.gulfam actually say?

Honestly? It's nearly impossible to tell. The transcript from this 686K-view video is almost entirely incoherent, cycling through disconnected phrases about education, relationships, and a single data point: "10% of body weight." There is no clear, reviewable medical claim here, which is its own kind of problem when a surgeon is posting to nearly a million viewers.

The only fragment with any clinical relevance is the reference to "10% of body weight," which appears to gesture at weight loss outcomes, likely in the context of GLP-1 receptor agonists given the video's categorization. But the surrounding sentences provide no context: no drug named, no mechanism explained, no patient population specified. The phrase arrives mid-sentence and then dissolves into "thank you."

When a credentialed surgeon posts health content that reaches hundreds of thousands of people, the standard for clarity should be higher than this. Viewers cannot make informed decisions based on content they cannot parse.

Does the science back this up?

If the "10% of body weight" figure refers to GLP-1 outcomes, the number itself is defensible but represents the lower end of what the evidence shows, and context matters enormously depending on which drug and which population you're talking about.

Semaglutide (Wegovy) at 2.4mg weekly produced mean weight loss of approximately 14.9% of body weight in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), with about one-third of participants losing more than 20%. Tirzepatide (Zepbound) pushed that further: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed mean reductions of up to 22.5% at the highest dose. Liraglutide (Saxenda) is closer to the 5-8% range in real-world use.

So "10% of body weight" is a reasonable ballpark for semaglutide in average clinical conditions, but presenting it as a standalone number without naming the drug, dose, or duration strips out everything a patient actually needs to evaluate whether a treatment is appropriate for them.

What did they get wrong (or right)?

The 10% figure is not wrong in isolation. What's wrong is everything around it, specifically the absence of everything around it. No drug named. No dose. No duration. No mention of side effects, which for GLP-1 agonists include nausea, vomiting, gastroparesis risk, and the still-debated question of muscle mass loss alongside fat loss (Biancalana et al., 2023, Diabetes Care).

The rest of the transcript is not a medical claim at all. Phrases like "you can't go anywhere down" and "I'd like to have a better education than you would have in your life" are not extractable health statements. They may reflect a translation or transcription issue, but that doesn't reduce the responsibility of a creator posting under the title "surgeon" to ensure their content communicates something accurate and actionable.

There's also a regulatory concern worth naming directly. Posting a phone number for appointments alongside surgical hashtags and GLP-1 adjacent content, without visible disclosure of risks, informed consent language, or evidence of proper telehealth licensure, does not meet the standard of responsible medical content creation.

What should you actually know?

GLP-1 receptor agonists are legitimate, well-studied medications with meaningful clinical evidence behind them. But "10% of body weight" is not a promise, a guarantee, or even a typical result for every drug in this class. Results depend on which medication, what dose, how long you take it, whether you pair it with lifestyle changes, and your individual metabolic profile.

Before pursuing any GLP-1 therapy, you should be working with a licensed provider who reviews your full medical history, screens for contraindications (including personal or family history of medullary thyroid carcinoma or MEN2 syndrome, per FDA labeling), and monitors you over time. A phone number in a TikTok caption is not a clinical intake process.

If you're in Pakistan and considering bariatric surgery or weight management medication, the standards for informed consent and provider accountability still apply. A surgeon with a large social following is not automatically a trustworthy clinical source, especially when the content they post cannot be fact-checked because it cannot be understood.

  • Ask any provider to name the specific drug, dose range, and expected timeline before agreeing to treatment.
  • Request documentation of side effects in writing, not just a verbal summary.
  • Verify that the platform or clinic you use is properly licensed in your jurisdiction.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

surgeon.dr.hafiz.gulfam · TikTok creator

686.5K views on this video

For appointment 03294686026 03096142525 #drgulfam #bashirhospital #sleevegestrectomy #hemorrhoids #dramralodhi #varicocele #infertile #drmushtaq

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced mean 14.9% body weight loss, not 10%, over 68 weeks in adults with obesity.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide produced up?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 22.5% mean weight loss at 15mg, significantly above the figure implied in this video.

What does the video say about liraglutide (saxenda) typically produces closer to 5-8% body weight loss?

Liraglutide (Saxenda) typically produces closer to 5-8% body weight loss in real-world settings, well below the 10% figure referenced.

What does the video say about glp-1 agonists carry fda-labeled contraindications including personal?

GLP-1 agonists carry FDA-labeled contraindications including personal or family history of medullary thyroid carcinoma and MEN2 syndrome; no content in this video acknowledges these.

What does the video say about muscle mass loss alongside fat loss during glp-1 therapy?

Muscle mass loss alongside fat loss during GLP-1 therapy is an active clinical concern, with Biancalana et al. (2023, Diabetes Care) noting the need for resistance training and protein intake monitoring.

What does the video say about a phone number in a tiktok caption does not substitute?

A phone number in a TikTok caption does not substitute for a licensed telehealth intake process with documented informed consent and contraindication screening.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by surgeon.dr.hafiz.gulfam, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.